Form 4: Theravance Biopharma SVP Sells Shares Under 10b5-1 Plan

Theravance Biopharma's SVP of Communications and Medical Affairs, Rhonda Farnum, sold 31,067 ordinary shares for approximately $18.75 per share under a pre-arranged 10b5-1 plan.

Summary

• Rhonda Farnum, Senior Vice President of Communications and Medical Affairs at Theravance Biopharma, Inc. (TBPH), reported the sale of ordinary shares.
• The transactions occurred on December 3, 2025, involving three separate sales.
• A total of 31,067 ordinary shares were disposed of by the reporting person.
• The weighted average sale prices for these transactions ranged from $18.7493 to $18.7508 per share.
• These sales were executed in accordance with a Rule 10b5-1 trading plan established on September 3, 2025.
• Following these reported transactions, Rhonda Farnum beneficially owns 277,695 ordinary shares.

Sentiment

Score: 5

Explanation: The filing reports a pre-planned sale of shares by a senior executive under a Rule 10b5-1 plan, which is a routine event for insider liquidity management and does not inherently signal positive or negative company performance.

Positives

• The share sales were conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned transaction for liquidity or diversification rather than a reaction to new, non-public information.

Negatives

• A senior executive sold a significant number of shares (31,067 shares), which some investors might interpret as a lack of confidence, despite the existence of a 10b5-1 plan.

Risks

• Potential for negative investor sentiment or misinterpretation regarding insider confidence, even though the sales were pre-planned under a 10b5-1 plan.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Shareholders: May observe the executive's share sale, which, despite being pre-planned, could lead to questions about insider confidence or future prospects.

Key Dates

Recommendation

The reported insider share sales by a senior executive were executed under a pre-arranged Rule 10b5-1 trading plan. Such planned transactions are common for executive liquidity and diversification and do not typically indicate a change in the company's fundamental outlook or warrant an immediate change in investment recommendation based solely on this filing.

Keywords

Theravance Biopharma, TBPH, Form 4, insider trading, share sale, executive compensation, 10b5-1 plan, Rhonda Farnum